Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects With Moderately to Severely Active Crohn's Disease Previously Treated With TNF Antagonist Therapy
Brief Summary: A medical research study in adult patients who have moderate to severe Crohn's disease designed to determine whether or not treatment with an experimental drug called ustekinumab (or CNTO1275) is safe or not and to determine if the treatment will reduce the symptoms of Crohn's disease.


Options:
A: Arm Label: Placebo (IP); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (IP) | Arm Label: Ustekinumab 1mg/kg (IP); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 1mg/kg (IP) | Arm Label: Ustekinumab 3 mg/kg (IP); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 3 mg/kg (IP) | Arm Label: Ustekinumab 6 mg/kg (IP); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 6 mg/kg (IP) | Arm Label: Placebo IV - Responder - Placebo SC (MP); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo IV - Responder - Placebo SC (MP) | Arm Label: Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP) | Arm Label: Ustekinumab IV - Responder - Placebo SC (MP); Type: PLACEBO_COMPARATOR; Interventions: Drug: Ustekinumab IV - Responder - Placebo SC (MP) | Arm Label: Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP) | Arm Label: Ustekinumab IV - Nonresponder - Placebo SC (MP); Type: PLACEBO_COMPARATOR; Interventions: Drug: Ustekinumab IV - Nonresponder - Placebo SC (MP) | Arm Label: Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP) | Intervention Type: DRUG; Name: Placebo (IP); Assigned to Arm(s): Placebo (IP) | Intervention Type: DRUG; Name: Ustekinumab 1mg/kg (IP); Assigned to Arm(s): Ustekinumab 1mg/kg (IP) | Intervention Type: DRUG; Name: Ustekinumab 3 mg/kg (IP); Assigned to Arm(s): Ustekinumab 3 mg/kg (IP) | Intervention Type: DRUG; Name: Ustekinumab 6 mg/kg (IP); Assigned to Arm(s): Ustekinumab 6 mg/kg (IP) | Intervention Type: DRUG; Name: Placebo IV - Responder - Placebo SC (MP); Assigned to Arm(s): Placebo IV - Responder - Placebo SC (MP) | Intervention Type: DRUG; Name: Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP); Assigned to Arm(s): Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC | Intervention Type: DRUG; Name: Ustekinumab IV - Responder - Placebo SC (MP); Assigned to Arm(s): Ustekinumab IV - Responder - Placebo SC (MP) | Intervention Type: DRUG; Name: Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP); Assigned to Arm(s): Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP) | Intervention Type: DRUG; Name: Ustekinumab IV - Nonresponder - Placebo SC (MP); Assigned to Arm(s): Ustekinumab IV - Nonresponder - Placebo SC (MP) | Intervention Type: DRUG; Name: Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP); Assigned to Arm(s): Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)
B: Arm Label: 001; Type: PLACEBO_COMPARATOR; Interventions: Drug: Group 1: Placebo | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Group 2 ustekinumab 130 mg | Arm Label: 003; Type: EXPERIMENTAL; Interventions: Drug: Group 3: ustekinumab approximately 6 mg/kg | Intervention Type: DRUG; Name: Group 2 ustekinumab 130 mg; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Group 3: ustekinumab approximately 6 mg/kg; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: Group 1: Placebo; Assigned to Arm(s): 001
C: Arm Label: Placebo IV; Type: PLACEBO_COMPARATOR; Interventions: Drug: Group 1: Placebo | Arm Label: Ustekinumab 130 milligram (mg); Type: EXPERIMENTAL; Interventions: Drug: Group 2 ustekinumab 130 mg | Arm Label: Ustekinumab approximately (~) 6 milligram per kilogram (mg/kg); Type: EXPERIMENTAL; Interventions: Drug: Group 3: ustekinumab approximately 6 mg/kg | Intervention Type: DRUG; Name: Group 1: Placebo; Assigned to Arm(s): Placebo IV | Intervention Type: DRUG; Name: Group 2 ustekinumab 130 mg; Assigned to Arm(s): Ustekinumab 130 milligram (mg) | Intervention Type: DRUG; Name: Group 3: ustekinumab approximately 6 mg/kg; Assigned to Arm(s): Ustekinumab approximately (~) 6 milligram per kilogram (mg/kg)
D: Arm Label: 001; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo SC | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 90 mg SC q12w | Arm Label: 003; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab 90 mg SC q8w | Arm Label: 004; Type: EXPERIMENTAL; Interventions: Drug: Placebo IV, Drug: Ustekinumab 90 mg SC q8w | Arm Label: 005; Type: EXPERIMENTAL; Interventions: Drug: Placebo SC, Drug: Ustekinumab 130 mg IV, Drug: Ustekinumab 90 mg SC q12w | Arm Label: 006; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo SC | Intervention Type: DRUG; Name: Placebo SC; Assigned to Arm(s): 001, 005, 006 | Intervention Type: DRUG; Name: Placebo IV; Assigned to Arm(s): 004 | Intervention Type: DRUG; Name: Ustekinumab 90 mg SC q8w; Assigned to Arm(s): 003, 004 | Intervention Type: DRUG; Name: Ustekinumab 130 mg IV; Assigned to Arm(s): 005 | Intervention Type: DRUG; Name: Ustekinumab 90 mg SC q12w; Assigned to Arm(s): 002, 005

Answer: A